137 related articles for article (PubMed ID: 24322028)
21. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.
Trevaskis JL; Griffin PS; Wittmer C; Neuschwander-Tetri BA; Brunt EM; Dolman CS; Erickson MR; Napora J; Parkes DG; Roth JD
Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G762-72. PubMed ID: 22268099
[TBL] [Abstract][Full Text] [Related]
22. Omega-3 phospholipids from fish suppress hepatic steatosis by integrated inhibition of biosynthetic pathways in dietary obese mice.
Rossmeisl M; Medrikova D; van Schothorst EM; Pavlisova J; Kuda O; Hensler M; Bardova K; Flachs P; Stankova B; Vecka M; Tvrzicka E; Zak A; Keijer J; Kopecky J
Biochim Biophys Acta; 2014 Feb; 1841(2):267-78. PubMed ID: 24295779
[TBL] [Abstract][Full Text] [Related]
23. [Clinical and histological features of non-alcoholic fatty liver disease].
Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
[TBL] [Abstract][Full Text] [Related]
24. Omega-3 fatty acids reduce hepatic steatosis and consequently attenuate ischemia-reperfusion injury following partial hepatectomy in rats.
Marsman HA; Heger M; Kloek JJ; Nienhuis SL; ten Kate FJ; van Gulik TM
Dig Liver Dis; 2011 Dec; 43(12):984-90. PubMed ID: 21840275
[TBL] [Abstract][Full Text] [Related]
25. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
Hookman P; Barkin JS
Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
[TBL] [Abstract][Full Text] [Related]
26. Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats.
Qin R; Zhang J; Li C; Zhang X; Xiong A; Huang F; Yin Z; Li K; Qin W; Chen M; Zhang S; Liang L; Zhang H; Nie H; Ye W
Arch Pharm Res; 2012 Jul; 35(7):1241-50. PubMed ID: 22864747
[TBL] [Abstract][Full Text] [Related]
27. Lowering the dietary omega-6: omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model.
Enos RT; Velázquez KT; McClellan JL; Cranford TL; Walla MD; Murphy EA
Nutr Res; 2015 May; 35(5):449-59. PubMed ID: 25934114
[TBL] [Abstract][Full Text] [Related]
28. Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease.
Kathirvel E; Morgan K; French SW; Morgan TR
Nutr Res; 2013 Nov; 33(11):932-41. PubMed ID: 24176233
[TBL] [Abstract][Full Text] [Related]
29. Dynamic expression of hepatic thioredoxin mRNA in rats with non-alcoholic fatty liver disease.
Duan XY; Zhao HP; Fan JG
J Dig Dis; 2010 Apr; 11(2):94-100. PubMed ID: 20402835
[TBL] [Abstract][Full Text] [Related]
30. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
Ito S; Yukawa T; Uetake S; Yamauchi M
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
[TBL] [Abstract][Full Text] [Related]
31. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy.
Cussons AJ; Watts GF; Mori TA; Stuckey BG
J Clin Endocrinol Metab; 2009 Oct; 94(10):3842-8. PubMed ID: 19622617
[TBL] [Abstract][Full Text] [Related]
32. Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents.
Leikin-Frenkel A; Goldiner I; Leikin-Gobbi D; Rosenberg R; Bonen H; Litvak A; Bernheim J; Konikoff FM; Gilat T
Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1205-13. PubMed ID: 18989145
[TBL] [Abstract][Full Text] [Related]
33. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
Samy W; Hassanian MA
Arab J Gastroenterol; 2011 Jun; 12(2):80-5. PubMed ID: 21684478
[TBL] [Abstract][Full Text] [Related]
34. Nonalcoholic fatty liver disease.
Paredes AH; Torres DM; Harrison SA
Clin Liver Dis; 2012 May; 16(2):397-419. PubMed ID: 22541706
[TBL] [Abstract][Full Text] [Related]
35. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
Hong XZ; Li LD; Wu LM
Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
[TBL] [Abstract][Full Text] [Related]
36. Effects of treatment with melatonin and tryptophan on liver enzymes, parameters of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease--14 months follow up.
Celinski K; Konturek PC; Slomka M; Cichoz-Lach H; Brzozowski T; Konturek SJ; Korolczuk A
J Physiol Pharmacol; 2014 Feb; 65(1):75-82. PubMed ID: 24622832
[TBL] [Abstract][Full Text] [Related]
37. A mouse model for nonalcoholic steatohepatitis.
Sundaresan S; Vijayagopal P; Mills N; Imrhan V; Prasad C
J Nutr Biochem; 2011 Oct; 22(10):979-84. PubMed ID: 21190824
[TBL] [Abstract][Full Text] [Related]
38. Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids.
El-Badry AM; Moritz W; Contaldo C; Tian Y; Graf R; Clavien PA
Hepatology; 2007 Apr; 45(4):855-63. PubMed ID: 17393510
[TBL] [Abstract][Full Text] [Related]
39. Investigation of anthropometric, biochemical and dietary parameters of obese children with and without non-alcoholic fatty liver disease.
Papandreou D; Karabouta Z; Pantoleon A; Rousso I
Appetite; 2012 Dec; 59(3):939-44. PubMed ID: 23000278
[TBL] [Abstract][Full Text] [Related]
40. A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice.
Kubota N; Kado S; Kano M; Masuoka N; Nagata Y; Kobayashi T; Miyazaki K; Ishikawa F
Clin Exp Pharmacol Physiol; 2013 Jul; 40(7):422-30. PubMed ID: 23611112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
